Advertisement
BMY vs PFE
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- BMY reported first-quarter 2026 revenue of $11.5 billion, up 3% year-over-year and exceeding estimates, with its Growth Portfolio up 12% to $6.2 billion.
- BMY has outperformed PFE year-to-date, with returns of approximately 10.34% compared to 7.51%.
- PFE provides a higher dividend yield at 6.53% versus BMY's 4.33%, attracting income-oriented investors.
- Both stocks trade in the healthcare sector with market caps around $119 billion for BMY and $150 billion for PFE, facing similar patent expiration risks.
- Recent analyst sentiment remains constructive for both, with price targets suggesting upside potential amid pipeline developments.
Introduction
Bristol-Myers Squibb (BMY) and Pfizer (PFE) are two leading biopharmaceutical giants often compared by investors seeking exposure to the healthcare sector. Both companies specialize in oncology and immunology treatments, offer attractive dividends, and navigate similar challenges like patent cliffs and pipeline advancements. This stock comparison analyzes their recent performance, financial metrics, and market positioning to help traders evaluate relative strength in the current environment. Value investors may favor dividend yields, while growth-oriented traders focus on momentum and catalysts, making this head-to-head relevant for diversified portfolios.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company focused on oncology, hematology, immunology, cardiovascular, and neuroscience therapies. In recent market activity, BMY shares have traded in the mid-to-upper $50s range, reflecting volatility around quarterly results. The company reported solid first-quarter 2026 revenue growth of 3% to $11.5 billion, driven by its Growth Portfolio which rose 12%, offsetting declines in legacy products. Sentiment has been bolstered by reaffirmed guidance and pipeline milestones, though broader sector pressures and competition have tempered gains. Year-to-date returns stand at 10.34%, with a trailing twelve-month (TTM) price-to-earnings (PE) ratio of 16.31 and market capitalization of approximately $119 billion.
PFE Overview and Recent Performance
Pfizer (PFE) develops innovative medicines across oncology, vaccines, rare diseases, and inflammation, with a broad portfolio including post-COVID products. Shares have hovered around the mid-$20s in recent weeks, influenced by pipeline updates and macroeconomic factors. The stock has shown resilience with year-to-date gains of 7.51%, trailing BMY but supported by its high dividend yield and analyst focus on upcoming catalysts like FDA approvals. Key metrics include a TTM PE ratio of 19.36, earnings per share (EPS) of $1.36, and market cap near $150 billion. Performance reflects steady revenue from established drugs amid normalization from pandemic-era peaks.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots, drawn from over 350 bots that trade thousands of tickers across diverse strategies and timeframes. Only the most suitable for current market conditions earn a spot among the 25 featured, highlighting tools with impressive stats like annualized returns up to 163.10%, win rates ranging from 51% to 88%, profit factors up to 11.70, and profit-to-drawdown ratios exceeding 17. These include swing trading agents, multi-ticker trend followers, and volatility-focused signals with average trade durations from hours to weeks. Traders can explore bots tailored to sectors like technology and industrials, each with unique risk management like take-profit/stop-loss corridors. Visit Trending AI Robots to discover options optimized for today's opportunities.
Head-to-Head Comparison
Both BMY and PFE operate as large-cap biopharma firms with heavy oncology exposure, but PFE's diversified model spans vaccines and rare diseases for broader revenue streams, while BMY emphasizes immunology and hematology. Growth drivers differ: BMY's recent portfolio expansion contrasts PFE's post-COVID stabilization. Momentum favors BMY with stronger YTD returns, though PFE edges on dividend yield. Risk factors include patent expirations for both, heightening competition, with BMY showing higher debt-to-equity at 231% versus PFE's 78%. Sector dynamics in healthcare amplify sentiment shifts from clinical data, positioning BMY for near-term catalysts amid relative stability.
Tickeron AI Verdict
Tickeron's AI tools currently lean toward BMY over PFE, based on superior year-to-date momentum, a recent earnings beat, and consistent trend positioning in recent market activity. While PFE's higher yield and pipeline breadth offer appeal, BMY's growth portfolio strength suggests higher probability of outperformance in the near term, subject to ongoing sector trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Buy and PFE is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 2 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).
- BMY’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 6 bullish TA indicator(s).
- BMY’s TA Score: 5 bullish, 4 bearish.
- PFE’s TA Score: 6 bullish, 2 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -0.24% price change this week, while PFE (@Pharmaceuticals: Major) price change was +0.65% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +6.56%, and the average quarterly price growth was +4.69%.
Reported Earning Dates
BMY is expected to report earnings on Jul 30, 2026.
PFE is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BMY | PFE | BMY / PFE | |
| Capitalization | 117B | 149B | 79% |
| EBITDA | 15B | 17.2B | 87% |
| Gain YTD | 8.271 | 8.791 | 94% |
| P/E Ratio | 16.00 | 20.01 | 80% |
| Revenue | 48.5B | 63.3B | 77% |
| Total Cash | 10.5B | 13.1B | 80% |
| Total Debt | 46.4B | 63.7B | 73% |
BMY | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 29 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 19 Undervalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 91 | 100 | |
SMR RATING 1..100 | 25 | 78 | |
PRICE GROWTH RATING 1..100 | 50 | 39 | |
P/E GROWTH RATING 1..100 | 68 | 42 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (5) in the Pharmaceuticals Major industry is in the same range as BMY (19). This means that PFE’s stock grew similarly to BMY’s over the last 12 months.
BMY's Profit vs Risk Rating (91) in the Pharmaceuticals Major industry is in the same range as PFE (100). This means that BMY’s stock grew similarly to PFE’s over the last 12 months.
BMY's SMR Rating (25) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (78). This means that BMY’s stock grew somewhat faster than PFE’s over the last 12 months.
PFE's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as BMY (50). This means that PFE’s stock grew similarly to BMY’s over the last 12 months.
PFE's P/E Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as BMY (68). This means that PFE’s stock grew similarly to BMY’s over the last 12 months.
| BMY | PFE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 52% | N/A |
| Stochastic ODDS (%) | 2 days ago 55% | 2 days ago 54% |
| Momentum ODDS (%) | 2 days ago 56% | 2 days ago 61% |
| MACD ODDS (%) | 2 days ago 46% | 2 days ago 41% |
| TrendWeek ODDS (%) | 2 days ago 56% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 50% |
| Advances ODDS (%) | 2 days ago 54% | 2 days ago 56% |
| Declines ODDS (%) | 12 days ago 54% | 11 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 64% | 2 days ago 54% |
| Aroon ODDS (%) | 2 days ago 54% | 2 days ago 60% |
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +0.40% | ||
| PFE - BMY | 59% Loosely correlated | +0.15% | ||
| AMGN - BMY | 57% Loosely correlated | +0.32% | ||
| NVS - BMY | 55% Loosely correlated | -0.55% | ||
| GSK - BMY | 53% Loosely correlated | +0.34% | ||
| ABBV - BMY | 52% Loosely correlated | +1.32% | ||
More | ||||
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +0.15% | ||
| BMY - PFE | 60% Loosely correlated | +0.40% | ||
| MRK - PFE | 55% Loosely correlated | -1.42% | ||
| AMGN - PFE | 53% Loosely correlated | +0.32% | ||
| NVS - PFE | 52% Loosely correlated | -0.55% | ||
| BIIB - PFE | 51% Loosely correlated | +0.05% | ||
More | ||||